Issues
-
Cover Image
Cover Image
Isocitrate dehydrogenase 1 mutations (mIDH1) are one of the most common metabolic gene mutations and occur in several types of malignancies, including intrahepatic cholangiocarcinoma. These mutations lead to the accumulation of (R)-2-hydroxyglutarate [(R)-2HG] in tumor cells and induce immunosuppression and immune evasion. Wu, Shi, Dubrot, and colleagues showed a dual effect of the mIDH1 inhibitor ivosidenib on antitumor immunity in an mIDH1-driven genetically engineered mouse model of cholangiocarcinoma in which CD8+ T-cell recruitment and production of IFNγ were markedly increased. Additionally, activation of TET2, a target of (R)-2HG, was restored, which promoted TET2-dependent upregulation of IFNγ target genes in tumor cells. Combining ivosidenib with immune checkpoint blockade therapy, such as an anti-CTLA4 antibody, overcame immunosuppression and showed potent synergy, suggesting this combination could be a therapeutic strategy in this disease. For more information, see the article by Wu, Shi, Dubrot, and colleagues on page 812. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
In This Issue
In the Spotlight
Reviews
Research Articles
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Atezolizumab shows promising activity with durable responses in immunotherapy-naive patients with a tumor mutation burden (TMB) of ≥16 mut/Mb across a variety of advanced solid tumors, but limited activity was observed in patients with a TMB between 10 and 16 mut/Mb.
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer
Single-cell RNA sequencing analysis of over 200,000 gastric cancer cells forms a comprehensive molecular atlas, identifying novel cell lineages and unique interactions between tumor cells and the surrounding microenvironment.
Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System
Neuroendocrine carcinomas (NEC) of the gastrointestinal system show similar histopathologic features and share some genomic features, but considerable differences exist between pancreatic NECs and nonpancreatic NECs.
DIPG Harbors Alterations Targetable by MEK Inhibitors, with Acquired Resistance Mechanisms Overcome by Combinatorial Inhibition
EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma
Targeted degradation of EP300 with a novel PROTAC agent in neuroblastoma cells was found to cause widespread loss of gene expression and cell death in vitro and in vivo.
PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity
PTP1B functions as an intracellular checkpoint that limits the cytotoxic activity of tumor-infiltrating T cells, and its deletion or inhibition can enhance the antitumor immunity of T cells and CAR T cells and the response to anti–PD-1 therapy.
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death
Depletion of mitochondrial iron with the drug ironomycin induced a dramatic loss in mitochondrial respiration and noncanonical BAX/BAK-dependent cell death that synergized with venetoclax in mouse and patient-derived models of leukemia.
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs
Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Integrative RNA-omics Discovers GNAS Alternative Splicing as a Phenotypic Driver of Splicing Factor–Mutant Neoplasms
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia
News in Brief
News in Depth
Research Watch
Technology
Immunology
Microbiome
Clinical Trials
Metabolism
Immunotherapy
Disease Prevalence
Drug Evaluation
Drug Resistance
Drug Combinations
Etiology
Breast Cancer
Disease Progression
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.